Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 6 institutions in 5 countries.
Judit C SágiDepartment of Genetics, Cell and Immunobiology, Semmelweis University, H-1089 Budapest, Hungary.
András GézsiDepartment of Measurement and Information Systems, Budapest University of Technology and Economics, H-1111 Budapest, Hungary.ORCID 0000-0003-1022-6356
Bálint Egyed2nd Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary.
Zsuzsanna Jakab2nd Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary.
Noémi BenedekDepartment of Pediatrics, Pécs University, H-7623 Pécs, Hungary.
Andishe AttarbaschiDepartment of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, A-1090 Vienna, Austria.ORCID 0000-0002-9285-6898
Stefan KöhrerRenate Panzer-Grümayer: Leukemia Biology Group, Children's Cancer Research Institute, A-1090 Vienna, Austria.
Jakub SipekDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, CZ-150 06 Prague, Czech Republic.
Lucie WinkowskaDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, CZ-150 06 Prague, Czech Republic.
Marketa ZaliovaDepartment of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, CZ-150 06 Prague, Czech Republic.ORCID 0000-0002-1639-7124
Stavroula AnastasopoulouChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, S-17177 Stockholm, Sweden.ORCID 0000-0002-4210-0064
Benjamin Ole WolthersDepartment of Paediatrics and Adolescent Medicine, Rigshospitalet, DK-2100 Copenhagen, Denmark.
Susanna RantaChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, S-17177 Stockholm, Sweden.
Csaba SzalaiDepartment of Genetics, Cell and Immunobiology, Semmelweis University, H-1089 Budapest, Hungary.ORCID 0000-0001-6562-0778
Gábor T Kovács2nd Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary.
Ágnes F SemseiDepartment of Genetics, Cell and Immunobiology, Semmelweis University, H-1089 Budapest, Hungary.ORCID 0000-0002-8709-2459
Dániel J Erdélyi2nd Department of Pediatrics, Semmelweis University, H-1094 Budapest, Hungary.ORCID 0000-0001-5544-9209
Semmelweis University · HUCharles University · CZKarolinska University Hospital · SERigshospitalet · DKSt Anna Children's Hospital · ATUniversity of Pecs · HU
Funding
Danish Cancer Society (Denmark) R150-A10181Danish Childhood Cancer Fund (Denmark) not addedHungarian Paediatric Oncology Network (Hungary) 07/MGYH-MGYGYT/2018János Bolyai Research Scholarship of the Hungarian Academy of Sciences (A Gézsi) not addedNational Research, Development and Innovation Office (NKFIH) Grants No. PD109200 (ÁF Semsei), PD134449 (A Gézsi) and K115861 (DJ Erdélyi)NCMG (Czech Republic) LM2018132New National Excellence Program of the Ministry for Innovation and Technology (Hungary) UNKP-19-3-IV (JC Sagi)St. Anna Kinderkrebsforschung (Austria) not addedSwedish Childhood Cancer Fund (Sweden) KP2017-0010, TJ2020-0082, TJ2019-0031
6 · The paper itself
Abstract
Despite improving cure rates in childhood acute lymphoblastic leukemia (ALL), therapeutic side effects and relapse are ongoing challenges. These can also affect the central nervous system (CNS). Our aim was to identify germline gene polymorphisms that influence the risk of CNS events. Sixty single nucleotide polymorphisms (SNPs) in 20 genes were genotyped in a Hungarian non-matched ALL cohort of 36 cases with chemotherapy related acute toxic encephalopathy (ATE) and 544 controls. Five significant SNPs were further analyzed in an extended Austrian-Czech-NOPHO cohort (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia. · full record | OpenQuestion